公开(公告)号：US20250009742A1

公开(公告)日：2025-01-09

申请号：US18699156

申请日：2022-10-12

Applicant: AM SCIENCES INC ,  KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Nakcheol JEONG ,  Misun LEE ,  Heewoo SIM ,  Myungjin KIM ,  Jung-Hee KIM ,  Soo Bong HAN ,  Young Sik JUNG ,  Hye jin KIM ,  Chang Soo YUN ,  Heeyeong CHO ,  Mee Hyein KIM ,  Joo Youn LEE

IPC: A61K31/501 ,  A61K31/4155 ,  A61K31/4162 ,  A61K31/422 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/506 ,  A61P31/20 ,  C07D231/12 ,  C07D231/16 ,  C07D231/56 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D471/04 ,  C07D491/052 ,  C07D491/056 ,  C07D495/04

Abstract: The present invention relates to a series of novel pyrazolylmethylurea derivatives, and the use thereof for the inhibition of capsid assembly and the prevention or treatment of viral diseases through the inhibition.

公开(公告)号：US20230248734A1

公开(公告)日：2023-08-10

申请号：US18001333

申请日：2021-06-08

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

Inventor： Soo Bong HAN ,  Jin Soo SHIN ,  Mee Hyein KIM ,  Eunhye JUNG ,  Ye Jin JANG ,  Hyuk LEE ,  Myoungkyu LEE ,  Dongsu KIM ,  Chang Soo YUN ,  Young Sik JUNG

IPC: A61K31/53 ,  A61K31/495 ,  A61K31/138 ,  A61K31/4402 ,  A61K31/137 ,  A61K31/4164 ,  A61K31/451 ,  A61K31/452 ,  A61K31/4453 ,  A61K31/40 ,  A61K31/445 ,  A61P31/14 ,  G01N33/50

CPC classification number: A61K31/53 ,  A61K31/495 ,  A61K31/138 ,  A61K31/4402 ,  A61K31/137 ,  A61K31/4164 ,  A61K31/451 ,  A61K31/452 ,  A61K31/4453 ,  A61K31/40 ,  A61K31/445 ,  A61P31/14 ,  G01N33/5091

Abstract: The present invention relates to the development of a composition for the treatment of novel SARS-coronavirus-2 infection. The drug efficacy was evaluated through CPE (Cytopathic Effect)-based assay method that measures how long the cells survive by infecting SARS-CoV-2 after receiving a drug library previously approved as a treatment for a specific disease from the Korea Chemical Bank and treating Vero cells with the drug, and an image-based assay that measures how much virus is reduced in infected cells. Through this, 16 kinds of drugs effective in the treatment of SARS-CoV-2 were re-positioned.